Latest
Sources
Trade Ideas
Speakers
Sign in
Go
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Original source ↗
| February 17, 2026 at 16:00 UTC |
Finnhub - MRK
No analysis available.
Trade Ideas
Ticker
Direction
Speaker
Thesis
Time
MRK
NONE
Finnhub News
—
—